LENZ reports Q3 revenue jump and CEO transition
LENZ Therapeutics reported a 50% increase in Q3 sales for VIZZ, announced a restructuring to cut costs, and named CFO Dan Chevallard as Interim CEO to replace Eef Schimmelpennink effective December 1.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed